Organization of Business and Going Concern (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 07, 2019	Aug. 25, 2020	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Jul. 31, 2020
Accumulated deficit			$ (488,724,179)		$ (488,724,179)		$ (452,062,905)
Working capital deficiency			(57,912,821)		(57,912,821)
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%.
Proceeds from related party					0	$ 10,000
Revenue			$ 0	$ 857,427	88,435	1,579,088
Medisource and Pantheon
Revenue					$ 0	$ 1,253,763
WWDT
Proceeds from related party		$ 1,500,000